Sarizotan in Parkinson Patients With L-Dopa-Induced Dyskinesia

Dopamine-Based Approaches, Dyskinesia, Serotonin-Based Approaches
Merck KGaA
Parkinson's Disease
Drug
Sarizotan HCl

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

Link to the current ClinicalTrials.gov record.
Agency: 
Merck KGaA
Phase: 
Phase II
Study Design: 
Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition: 
Parkinson's Disease
Intervention type: 
Drug
Intervention Name: 
Sarizotan HCl